Philip Low

Philip Low has a diverse work experience in the field of biomedical research and drug discovery. In 1976, they joined Purdue University as the Corley Distinguished Professor of Chemistry and later became a part of the Purdue Institute for Drug Discovery. During their time at Purdue University, they focused on improving the quality of life by engaging in drug discovery across disciplines and institutions, translating basic research into clinical applications, and developing new diagnostic tools and treatments.

In 1995, Philip co-founded Endocyte, Inc., where they served as the Chief Science Officer, Board Member, and contributed to the development of ligand targeted imaging and therapeutic agents for diagnosing and treating multiple human cancers. Philip remained with Endocyte until 2018.

Philip continued their entrepreneurial journey by co-founding On Target Laboratories, LLC in 2011, where they served as the Co-Founder and Chief Science Officer. The company focused on designing and developing tumor-targeted near infrared fluorescent dyes to aid cancer surgeons in locating and removing malignant lesions.

In 2017, Philip co-founded Novosteo, Inc., a company dedicated to designing and developing targeted therapies to accelerate the rate of bone fracture repair and reduce complications associated with bone reconstruction procedures and other bone-related conditions.

In 2018, they co-founded ErythroCure Inc., which aimed to develop novel therapies for Plasmodium falciparum malaria and sickle cell disease by targeting pathways that destabilize erythrocyte membranes.

Philip's entrepreneurial pursuits continued with their founding roles at Eradivir Inc. in 2020, where they focused on designing, synthesizing, and testing targeted therapies for viral diseases, and MorphImmune, Inc., which aimed to selectively target and reprogram dysregulated immune cells to address significant unmet medical needs.

In 2019, Philip co-founded Umoja Biopharma Inc., a company developing a sensitively controllable universal CAR T cell therapy for the treatment of both liquid and solid tumors.

Overall, Philip Low's career has spanned various roles in academia, research, and entrepreneurship, with a focus on drug discovery, targeted therapies, and improving medical treatments and diagnostics.

Philip Low began their education at Brigham Young University in 1965, where they pursued a Bachelor of Science degree in Chemistry. Philip attended this institution until 1971. Subsequently, they enrolled at UC San Diego, where they completed their Ph.D. in Biochemistry between 1971 and 1975.